Sino Biopharmaceutical (1177.HK) — market event timeline

NashNova tracks 2 market events mentioning Sino Biopharmaceutical (1177.HK) between 2026-06-04 and 2026-07-08, each with a dated one-line analysis of how the event relates to the asset.

  1. AstraZeneca Signs Respiratory Drug Licensing Deal with CSPC, Worth Up to $1.9 Billion

    Direct beneficiary of the deal — its subsidiary Chia Tai Tianqing licensed out TQC3721 for up to $1.9 billion in total deal value, directly boosting revenue expectations.

  2. Maikeoute Passes HKEX Hearing, Core Product MT1013 Enters Phase III Clinical Trial

    A leading domestic pharmaceutical company in nephrology and metabolic diseases. The approval of new CKD-SHPT therapies would reshape the competitive landscape of this niche market.

For research and information only — not investment advice.

Sino Biopharmaceutical (1177.HK) — News & AI Analysis · NashNova